Tegretol vs Depakote

How they're similar

Carbamazepine and valproate share a lot in the mood-stabilizer role.

• Both started as seizure medications and were later shown to help in bipolar disorder. Both are used in mania, in mixed states, and in maintenance treatment.
• Both are considered particularly useful in mixed states and rapid cycling, where lithium can be less effective.
• Both require blood level monitoring to keep the dose in a therapeutic range. Both require baseline and ongoing lab work, including a complete blood count and liver function tests.
• Both are teratogens. Neither is a first choice in someone who could become pregnant unless the case for it is strong and contraception is reliable.
• Both interact with a long list of other medications, though the pattern of interaction is different for each.
• Both can cause weight change, sedation, and tremor, and both need a gradual taper if they're stopped.
• Both are available as generics, and both have been used in psychiatry for decades, so the safety and monitoring pattern is well understood.

In day-to-day terms, starting either one means committing to labs. It also means telling every other clinician you see that you're on it, because interactions with everyday medications, including antibiotics and birth control, are real.

How they differ

The differences are large. They act on different targets, they carry different serious risks, and they require different monitoring. The table below covers the core points, with more detail underneath.

Carbamazepine is a sodium channel blocker and it does something unusual. It induces the liver enzymes that break it down, so its own level drops in the first few weeks of treatment. This is called auto-induction, and it means the dose usually has to go up during the first month or so to keep the level in range. It also induces CYP3A4, which is the enzyme that breaks down a huge number of other drugs. That's why carbamazepine can make birth control pills fail, can drop the level of several antipsychotics and antidepressants, and can interact with everything from certain antibiotics to blood thinners. If a patient is on more than a few medications, this alone can be a reason to pick something else.

Valproate works through several mechanisms that aren't fully mapped out, including sodium channel effects, some GABA effects, and calcium channel effects. Its interaction pattern is different. It inhibits enzymes rather than induces them, so it can raise the level of some other drugs, including lamotrigine, where the dose of lamotrigine has to be cut when valproate is added.

The serious risks are the reason both drugs get careful conversations before starting. Carbamazepine can cause Stevens-Johnson syndrome and toxic epidermal necrolysis, which are severe skin reactions that can be fatal. The risk is much higher in patients with the HLA-B1502 genetic variant, which is more common in Han Chinese, Thai, Filipino, Malaysian, South Asian, and Indonesian populations. Genetic screening is recommended before starting carbamazepine in patients of those ancestries. A separate variant, HLA-A3101, is associated with a range of severe reactions in patients of European or Japanese ancestry, and screening is also considered there. Carbamazepine can also cause aplastic anemia and agranulocytosis, both rare but serious blood problems, which is part of the reason for regular CBC monitoring. It commonly causes hyponatremia, low sodium, through a syndrome called SIADH.

Valproate doesn't carry the HLA-linked skin reaction risk, but it has its own serious risks. Hepatotoxicity, a rare but potentially fatal liver injury, is the reason for baseline and ongoing liver function tests, and the risk is highest in children under two on multiple anticonvulsants. Pancreatitis can happen at any point in treatment. Thrombocytopenia, low platelets, is common enough that it shows up on routine CBC monitoring. Hyperammonemia can occur even with normal liver function tests and can cause confusion or sedation. Valproate is a well-established teratogen, and current guidance treats it as contraindicated in pregnancy because of high rates of neural tube defects and effects on cognitive development in children exposed in utero. It also causes weight gain and is associated with polycystic ovary syndrome features in young women.

The blood level targets are different because the drugs are dosed differently. Carbamazepine is usually kept between 4 and 12 mcg/mL, though many prescribers target the middle of that range. Valproate is usually kept between 50 and 125 mcg/mL. Levels are drawn as troughs, right before the next dose, so timing matters.

Side effect tendencies

The everyday side effects overlap in some places and differ in others.

Both can cause sedation, dizziness, and tremor, especially early in treatment or after a dose increase. Both can cause GI upset, and taking the dose with food often helps. Both can cause hair thinning, though this is more often mentioned with valproate.

Carbamazepine is more associated with rash, which is common enough that any new rash on carbamazepine gets attention right away. It's more associated with low sodium, which shows up as fatigue, confusion, headaches, or nausea, and is more common in older adults. It's more associated with double vision or blurred vision when the level is high.

Valproate is more associated with weight gain, tremor that lasts, hair loss, and menstrual changes in young women. It's more associated with elevated ammonia even with normal liver enzymes, which can present as sedation or subtle confusion. It's more associated with easy bruising or nosebleeds because of the effect on platelets.

Neither is a mild medication. Both are worth taking seriously and both are worth staying on lab monitoring for, indefinitely, if a patient is on them long term.

What tips the choice

Because valproate is used more often as a first-line mood stabilizer in current practice, the more common question is why a clinician would pick carbamazepine instead.

Carbamazepine tends to be considered when someone hasn't responded to lithium and valproate, when the pattern is heavy on mixed states or rapid cycling, or when weight gain from valproate is a real barrier. It's also sometimes chosen because it's roughly weight-neutral, which matters for some patients. In practice, though, the interaction profile and the HLA-linked risks make it a second or third choice for most prescribers.

Valproate tends to be chosen for acute mania, for mixed states, for rapid cycling, and for patients who haven't done well on lithium. It works quickly in mania and can be loaded to a therapeutic level within a few days, which matters in inpatient settings. It's generally not a first choice in someone who could become pregnant.

A few practical scenarios. A 40-year-old man with rapid cycling bipolar and no medication list could reasonably start on either, and most prescribers would pick valproate. A 28-year-old woman of childbearing age with bipolar mania probably shouldn't be on valproate at all if there are reasonable alternatives, and lithium or an atypical antipsychotic would be more appropriate. A patient of Han Chinese ancestry being considered for carbamazepine needs HLA-B*1502 testing before starting. A patient on birth control who needs a mood stabilizer is a poor fit for carbamazepine unless the birth control plan is adjusted. None of these are firm rules, and the prescriber weighs the whole picture.

Common questions

Why do I need blood level monitoring on these medications? Both drugs have a therapeutic window, meaning the level needs to be high enough to work but not so high that it causes side effects or toxicity. Levels also help sort out whether a medication is failing because of the drug or because the dose is too low. Levels are usually drawn as troughs, right before the next dose, and are checked more often at the start and after any dose change. Once the level is stable, they're checked less often, but they don't go away entirely.

Can I take carbamazepine if I'm on birth control? It's a complicated combination. Carbamazepine induces the enzyme that breaks down estrogen and progestin in birth control pills, and can drop their level enough to make them fail. This includes the pill, the patch, the ring, and to some extent the implant. Non-hormonal options, or a higher-dose hormonal option combined with a backup method, are usually the way this is handled. It's a conversation to have with both the psychiatrist and the person managing contraception.

Which one is more dangerous? Neither is a mild medication. Carbamazepine carries the risk of severe skin reactions, which are rare but serious and are the reason for HLA testing in certain ancestries. Valproate carries hepatotoxicity, pancreatitis, and a well-established risk of birth defects. They're different risks, not one clearly worse than the other. Both are safe for the vast majority of people who take them with monitoring, and both can cause serious problems in a small number.

Can I switch from one to the other? Yes, and it's done routinely when one isn't working or isn't tolerated. The switch is usually a cross-taper, gradually lowering one while introducing the other, because stopping either one suddenly in someone with bipolar disorder or a seizure history isn't safe. The plan should be set with a prescriber, and blood levels are usually checked during and after the switch.

Is one better for maintenance versus acute mania? Both are used in both roles. Valproate is more often chosen for acute mania because it can be loaded quickly to a therapeutic level and works within days. Carbamazepine is a slower start because of auto-induction, and levels have to be built up over weeks. For maintenance, both are used, though lithium remains the strongest evidence base and is often preferred if it's tolerated.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Carbamazepine prescribing information.
2. U.S. Food and Drug Administration. Valproate prescribing information.
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder.
4. MedlinePlus, U.S. National Library of Medicine.
5. National Institute of Mental Health. Bipolar disorder.